Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Stemline Therapeutics, Inc. securities (NASDAQ:STML): (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Stemline investors under the federal securities laws.
To join the Stemline class action, go to http://www.rosenlegal.com/cases-1048.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and (2) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1048.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
